1.5-Tesla Multiparametric-Magnetic Resonance Imaging for the detection of clinically significant prostate cancer

Multiparametric-magnetic resonance imaging (mp-MRI) is the main imaging modality used for prostate cancer detection. The aim of this study is to evaluate the diagnostic performance of mp-MRI at 1.5-Tesla (1. 5-T) for the detection of clinically significant prostate cancer.

In this ethical board approved prospective study, 39 patients with suspected prostate cancer were included. Patients with a history of positive prostate biopsy and patients treated for prostate cancer were excluded. All patients were examined at 1.5-T MRI, before standard transrectal ultrasonography-guided biopsy.

The overall sensitivity, specificity, positive predictive value and negative predictive value for mp-MRI were 100%, 73.68%, 80% and 100%, respectively.

Our results showed that 1.5 T mp-MRI has a high sensitivity for detection of clinically significant prostate cancer and high negative predictive value in order to rule out significant disease.

Clujul medical (1957). 2017 Jan 15 [Epub]

Cristian Popita, Anca Raluca Popita, Adela Sitar-Taut, Bogdan Petrut, Bogdan Fetica, Ioan Coman

Radiology and Medical Imaging Department, "Prof. Dr. Ion Chiricuţă" Oncology Institute, Cluj-Napoca, Romania; Radiology and Medical Imaging Department, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Internal Medicine Department, New Blue Life Medical Center, Cluj-Napoca, Romania., Department of Urology, "Prof. Dr. Ion Chiricuţă" Oncology Institute , Cluj-Napoca, Romania; Department of Urology , Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Department of Pathology, "Prof. Dr. Ion Chiricuţă" Oncology Institute, Cluj-Napoca, Romania.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe